PHARMACOLOGY

Bhasin, S., Storer, T. W., Berman, N., et al. (1996). New England Journal of Medicine, 335(1), 1-7.

43 men were randomized to placebo or 600mg/week testosterone enanthate, with or without strength training, for 10 weeks. Testosterone increased fat-free mass, muscle size, and strength even without exercise, with the largest gains in the group that combined testosterone with training. The landmark study establishing that supraphysiologic testosterone drives muscle growth independent of exercise.

Yu, J-G., Bonnerud, P., Eriksson, A., Stål, P. S., Tegner, Y., Malm, C. (2014). PLoS ONE, 9(9), e105330.

Muscle biopsies from long-term AAS users versus non-users showed significantly larger fiber area in both type I and type II fibers, along with more myonuclei per fiber, in the long-term users. Structural, biopsy-level evidence of the muscular adaptations behind long-term AAS use.

Fernandes, M. M., Batista, P. G., Chagas, C. V. R., Silva, R. R. A. S., Santos, F. M., Lenzi, M. C., et al. (2026). Echocardiography, 43(9), e70611.

Pooled 40 observational studies (1,906 strength-trained athletes, 95% male) comparing AAS users to non-using controls on heart structure and function. Structural changes, thickening of the heart's walls, were detectable in under 6 months, before any drop in pumping function showed up, and worsened progressively with more years of use, with the largest drop in ejection fraction (-7.39%) and the largest increase in heart mass appearing beyond 6 years of use. Some measures of heart function were already abnormal at every duration studied, including short-term use, and didn't track cleanly with how long someone had used. The cardiovascular cost of AAS use starts earlier and compounds longer than lifters tend to assume.

Kouri, E. M., Pope, H. G. Jr., Katz, D. L., Oliva, P. (1995). Clinical Journal of Sport Medicine, 5(4), 223-228.

Compared fat-free mass index (FFMI, lean body mass adjusted for height) across 157 male athletes, 83 confirmed anabolic-androgenic steroid users and 74 non-users. Natural, drug-free athletes topped out at an FFMI of 25.0, a well-defined ceiling in this sample, while steroid users routinely exceeded it, some well past 30. Became the standard sports-science reference point for the approximate natural genetic ceiling in men, separating the two groups with roughly 95% accuracy in this sample. Genetic outliers occasionally exceed 25 naturally, a strong reference point, not an absolute rule.

Sergeeva, K. V., Miroshnikov, A. B., Smolensky, A. V. (2019). Human Physiology, 45, 452-460.

Pooled results from 11 randomized controlled trials found growth hormone administration significantly increased lean body mass in healthy young adults, but did not significantly improve muscle strength versus placebo. The lean mass gain appears to be driven substantially by water retention rather than genuine muscle fiber growth, an important, unglamorous finding against the common assumption that GH is a direct muscle-builder.